At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete ...

Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1- At lower doses, patients maintained the improvem ...

Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.

Dr. Geetika Sabharwal has been honored with a 2025 Global Recognition Award for her sustained contributions to allergy and ...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...

PHAT remains a Hold as VOQUEZNA revenue ramps and opex improves, but leverage, dilution and valuation risk persist.

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis ...

As of Thursday, January 08, Phathom Pharmaceuticals, Inc.’s PHAT share price has dipped by 15.15%, which has investors ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.